Illumina (NASDAQ:ILMN) Director Sells $32,758,501.85 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 225,067 shares of Illumina stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. The trade was a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Illumina Stock Down 1.2%

Shares of NASDAQ ILMN traded down $1.76 during mid-day trading on Thursday, reaching $143.24. The company had a trading volume of 2,006,814 shares, compared to its average volume of 1,636,244. Illumina, Inc. has a twelve month low of $78.55 and a twelve month high of $155.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a market capitalization of $21.67 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The stock’s 50 day moving average is $128.31 and its 200-day moving average is $129.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $0.97 earnings per share. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ILMN shares. Piper Sandler dropped their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Stifel Nicolaus upped their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday. Evercore restated an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Finally, Canaccord Genuity Group decreased their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $137.75.

Institutional Investors Weigh In On Illumina

A number of hedge funds have recently bought and sold shares of the company. Capital World Investors raised its position in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the last quarter. WCM Investment Management LLC raised its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Invesco Ltd. raised its position in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after buying an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the last quarter. Finally, Morgan Stanley raised its position in shares of Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after buying an additional 1,005,474 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.